Back to catalogue
№ 185 24 filings · 2021-08-11 → 2026-03-23

GOODWIN PLC

GDWN
Industrial Goods and Services Share price 18,460p Market cap £1.4bn Overall fit 400 /1000

Excellent operating leverage and quality balance sheet but only tangential AI exposure, and the shares already discount the 100% profit doubling. March 2026 trading update signals cooling order book, lost tenders and possible dividend cut — inconsistent with a record-high price.

Fair value range 12,500p–16,500p Mid case · £1.1bn
Absolute upside -22.7% vs current market cap
Conviction 3/5 confidence in overvalued call
Supports the call
  • clean IFRS disclosure with segment-level margin data
  • explicit FY26 guidance of >£71m trading profit
  • consistent multi-year delivery track record
Limits the call
  • FY27 base uncertain given order-book cooling from £365m to £288m
  • appropriate P/E multiple debatable after 2x share price move
Methodology

Forward P/E 18-25x on FY26E EPS ~680p

In one line · bull case

High-quality UK specialist engineer with genuine operating leverage and multi-decade defence/nuclear backlog, but shares at 30x forward earnings already price in the profit doubling.

In one line · biggest risk

Order book has peaked (£365m→£288m in 4 months), two large tenders lost, and the Board is signalling a dividend cut — the market is priced for continued acceleration that leading indicators no longer support.

Drivers
AI beneficiary 28 /100
Only tangential AI-buildout exposure via LNG valves for gas-fired data-centre power; not a picks-and-shovels beneficiary.
Operating leverage 78 /100
H1 FY26 revenue +27% drove trading profit +117%; gross margin +630bps to 49.3%.
Earnings vs expectations 72 /100
Consistent beats/reiterations since FY22; first cautionary note in March 2026 update.
Growth momentum 72 /100
100% profit growth guided for FY26; leading indicators suggest FY27 will decelerate.
Moat 65 /100
Vertical foundry-to-machining integration, nuclear/defence qualifications, patent-protected niches (Duvelco, AVD, Soluform).
Earnings quality 68 /100
Reasonably clean; IRS swap adjustments separated; some WIP/contract-asset volatility.
Management quality 75 /100
Family-controlled 140+ years, disciplined capital allocation, candid dividend policy revision.
Cyclicality 60 /100
Capital goods, LNG, mining, jewellery — moderately cyclical with long-cycle defence/nuclear offset.
Leverage 25 /100
£5.8m net debt at Oct 2025; £53m post-special dividend (46% gearing) — still moderate.
Value-trap signals · 5
  • Order book declined from £365m (Oct 2025) to £288m (Feb 2026)
  • Two large tenders lost in recent quarter (€18m Estonia radar, £45m Sellafield)
  • Board actively considering reducing dividend policy
  • Goodwin family sold 122k shares at Nov 2025 (1.6% of capital) near price peak
  • Middle East LNG customers requesting delayed dispatch

GOODWIN PLC (GDWN) — Investment Research Note

Executive summary

Goodwin PLC is a UK-family-controlled specialist engineering group operating in two divisions — Mechanical Engineering (steel foundry, precision machining, dual-plate & axial nozzle valves, submersible slurry pumps, Easat radar systems, and the nascent Duvelco polyimide business) and Refractory Engineering (jewellery investment casting powders, cristobalite/perlite/vermiculite, AVD lithium-battery fire extinguishers, Soluform bags). Trading profits have inflected sharply from £17m in FY22 to a guided £71m+ for FY26 2025-10 trading update, driven by nuclear decommissioning (Sellafield SSBs & 63-can racks), naval defence castings (Northrop Grumman MoU with $200m potential 2025-09 trading update), LNG valve demand, and record refractory volumes. The single most important valuation point today: the shares at 20,650p already discount the doubling of profits and a continuation of the recent trajectory, while the March 2026 trading update reveals a cooling order book (£288m vs £365m in October), two lost tenders, delayed Middle East LNG dispatches, and a Board actively considering reducing its dividend policy — a combination inconsistent with the price paid.

Fair value estimate

Range: 12,500p – 16,500p per share (implied market cap £940m – £1,240m)

Methodology: forward P/E on FY26E earnings, cross-checked against FY27 normalised.

  • H1 FY26 EPS = 351.7p 2025-12 half-year; guided FY26 trading profit >£71m 2025-10 trading update → ~£53m post-tax → EPS ~680p
  • I apply 18–25x to FY26 EPS. Industrial capital-goods peers with defence/nuclear content typically trade 15–22x; Goodwin merits a modest premium for vertical integration and patent-protected niches, offset by family control, cyclicality and the cooling order book.
  • Cross-check: FY27 normalised trading profit ~£75-80m (Northrop ramp + Duvelco start) → EPS ~750p, at 20x = 15,000p.

Mid-point ~14,500p implies market cap ~£1,090m, vs current £1,576m. Absolute downside: ~30%.

Sector context

Confirmed: Industrial Goods and Services (specialist engineering / capital goods). Goodwin's quality profile is above the typical UK-listed industrial: unusually high gross margin (49.3% H1 FY26), vertical integration foundry→machining→valves→pumps, patent-protected niches (X-Sil, AVD, Duvelco polyimide, Soluform), and net cash / very low leverage. Growth momentum currently well above sector norm.

Listed peers: Rotork (industrial flow control valves), Melrose / Chemring / Avon Technologies (UK defence/industrial), IMI plc (specialist engineering, flow control). Not a perfect peer set given Goodwin's mix.

Investment thesis

  • Operating leverage inflection is real and visible. H1 FY26 revenue +27% drove trading profit from £17.1m to £37.2m (+117%); trading margin expanded from 16.1% to 27.4% and gross margin from 43.0% to 49.3% 2025-12 half-year. This proves that the significant capex programme (Goodwin International expansion, Goodwin Steel Castings pit space, US-funded 4x 9MeV radiography facilities 2024-09 trading update) is beginning to absorb high-throughput/high-price defence and nuclear work.
  • Multi-decade defence/nuclear backlog is unusually visible. Northrop Grumman MoU covers 4 US submarine programmes, initial $16m order with expected escalation "over $200m" as US funding releases 2025-09 trading update; Sellafield 63-can racks framework (100 racks contracted, potentially 240) and 29-tonne Self-Shielded Boxes running at 10/month 2024-09 & 2025-03 trading updates. These are qualified-supplier positions with essentially insurmountable barriers to entry.
  • Optionality on Duvelco polyimide — patent-pending, £12.5m plant with initial ~£40m/yr capacity, addressing a large global market with limited competition 2022-08 final results. Now delayed to FY27 initial contribution 2026-03 trading update but represents structural long-tail upside not in current earnings.

Key risks

  • Order book is cooling and the March 2026 update was quietly cautionary. Backlog fell from £365m (Oct 2025) to £330m (Oct H1) to £288m (Feb 2026); Easat lost a €18m Estonia coastal radar tender and Goodwin International lost a >£45m Sellafield tender 2026-03 trading update. Combined with Middle East LNG customers delaying dispatches, this signals FY27 could deliver a step-down rather than continued growth.
  • Dividend policy under active review. Board explicitly stated it is considering reverting to the old 38%-of-earnings+D&A formula or lower 2026-03 trading update. After a £40m special dividend paid Nov 2025 that pushed gearing to 46%, this signals capital-preservation concerns not previously flagged.
  • Cyclical exposure — jewellery, mining, oil/LNG, radar — with limited pricing power on the refractory side. Chairman notes "lack of confidence by the general public starting to colour their spending habits" 2026-03 trading update. Persistently high gold/silver prices are weighing on jewellery casting.

Operating leverage

The clearest leverage evidence is the H1 FY26 result: revenue +27% delivered trading profit +117% (£17.1m→£37.2m). Gross margin rose 630bps to 49.3% and trading margin rose 1,130bps to 27.4% 2025-12 half-year. Cost base is fixed-heavy: substantial foundry infrastructure, £125m of PPE, group centre costs of ~£2.2m/half that don't scale with revenue. Segment-level, Mechanical went from £13.8m to £30.8m operating profit on a £74m→£103m external revenue base — an ~60% incremental margin on the additional turnover. The US-Government-funded radiography facilities 2024-09 trading update and Goodwin International's new 1.5-acre facility 2021-08 final results add capacity without proportional cost increase. If FY27 revenue exceeds market expectations by 10–20%, incremental trading profit at these ~50-60% drop-through rates would be material — but the recent order-book cooling constrains this optionality.

Value-trap signals

  • Order book has peaked and is now declining (£365m→£288m over 4 months) — a leading indicator that could roll into revenue in FY27.
  • Two large tenders lost in the recent quarter including a strategically important Sellafield bid.
  • Dividend policy under downward review at the same time as the price is at record highs — management is signalling caution the price does not reflect.
  • Family placing at Nov 2025: Goodwin family sold 122k shares (1.6% of capital) at high prices 2025-11 placing — insider distribution near the peak.

Earnings vs expectations

Group does not ordinarily provide forward guidance. Where guidance has been given (rare), it has been beaten or reiterated:

  • Sept 2025 trading update flagged strong momentum; Oct 2025 upgraded to ">£71m" (100% up on FY25) — a substantial pre-announced beat vs prior year expectations 2025-10 trading update.
  • March 2026 update reiterated "in line with expectations" but with visibly less enthusiasm and specific negatives on tenders and Middle East timing.
  • Half-year results have consistently exceeded prior comparatives since FY22.

Pattern: consistent delivery and positive surprises since FY22, with the March 2026 update the first material caution in this period.

Conviction

3 — moderate

Anchoring factors: (i) clean, IFRS-audited disclosure and clearly stated forward guidance for FY26; (ii) consistent track record of delivering the trajectory management describes; (iii) segment reporting and margin data allow the operating-leverage math to be triangulated.

Limiting factors: (i) FY27 base is genuinely uncertain given the order-book decline, lost tenders and dividend policy review — the "right" P/E multiple depends heavily on whether FY26 is a peak or a plateau; (ii) Duvelco's contribution timing keeps slipping.

Driver scoring rationale

  • ai_beneficiary (28): Only tangential exposure via LNG valves for gas-fired data-centre power; no direct AI-driven revenue line.
  • operating_leverage (78): Demonstrated: +27% revenue → +117% profit in H1 FY26.
  • earnings_surprise_trend (72): Consistent beats/reiterations; March 2026 update introduces first caution.
  • cyclicality (60): Capital goods, mining, LNG, jewellery — moderately cyclical.
  • moat (65): Vertical integration + nuclear/defence qualifications + patents; family-run 140+ years.
  • leverage (25): Low net debt of £5.8m pre-special-dividend; ~£53m post; robust balance sheet.
  • earnings_quality (68): Clean audit, IRS swap adjustments called out; some WIP/contract asset volatility.
  • management_quality (75): Family-run, disciplined capital allocation, candid disclosure, willingness to revise dividend policy prudently.
  • growth_momentum (72): 100% profit growth guided; slight deceleration signal into FY27.

Overall score rationale

Weak AI-receiver fit (~30%), strong operating leverage (75%+), but valuation is stretched (30x forward P/E after a doubling in the share price over 12 months) and the order-book/tender/dividend signals introduce clear downside risk. Downside protection is decent but not enough to save the fit. Overall score in the low-mid range.

Filings consulted · 24

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-03-23Trading Update2026-03-23_9486732_trading-update.md0.85
  2. 2025-12-16Half Year Report2025-12-16_9298605_half-year-report.md0.77
  3. 2025-11-14Placing OF Shares IN Goodwin Plc2025-11-14_9232984_placing-of-shares-in-goodwin-plc.md0.59
  4. 2025-10-27Trading Update2025-10-27_9195045_trading-update.md0.72
  5. 2025-10-01Result OF Agm2025-10-01_9144443_result-of-agm.md0.26
  6. 2025-09-24Trading Update Amp Strategic Collaboration Agreement2025-09-24_9128296_trading-update-amp-strategic-collaboration-agreement.md0.72
  7. 2025-08-14Posting OF Annual Report And Accounts2025-08-14_9053479_posting-of-annual-report-and-accounts.md0.81
  8. 2025-03-19March 2025 Trading Update2025-03-19_8786512_march-2025-trading-update.md0.55
  9. 2024-12-17Half Year Report2024-12-17_8614849_half-year-report.md0.58
  10. 2024-10-02Result OF Agm2024-10-02_8457940_result-of-agm.md0.20
  11. 2024-09-25September 2024 Trading Update2024-09-25_8438668_september-2024-trading-update.md0.55
  12. 2024-08-22Posting OF Annual Report And Accounts2024-08-22_8380738_posting-of-annual-report-and-accounts.md0.62
  13. 2024-03-14March 2024 Trading Update2024-03-14_8086784_march-2024-trading-update.md0.38
  14. 2023-12-20Half Year Report2023-12-20_7952672_half-year-report.md0.41
  15. 2023-09-29Result OF Agm2023-09-29_7787345_result-of-agm.md0.14
  16. 2023-08-29Posting OF Annual Report And Accounts2023-08-29_7723250_posting-of-annual-report-and-accounts.md0.43
  17. 2022-12-20Half Year Report2022-12-20_7184423_half-year-report.md0.23
  18. 2022-10-05Result OF Agm2022-10-05_7247842_result-of-agm.md0.07
  19. 2022-08-19Posting OF Annual Report And Accounts2022-08-19_7186852_posting-of-annual-report-and-accounts.md0.24
  20. 2022-08-03Final Results2022-08-03_6958940_final-results.md0.25
  21. 2021-12-15Half Year Report2021-12-15_6831923_half-year-report.md0.23
  22. 2021-10-06Result OF Agm2021-10-06_6712700_result-of-agm.md0.07
  23. 2021-08-31Posting OF Annual Report And Accounts2021-08-31_6694241_posting-of-annual-report-and-accounts.md0.24
  24. 2021-08-11Final Results2021-08-11_6499414_final-results.md0.10

This research note was authored by a large language model after reading 24 regulatory filings published between 2021-08-11 and 2026-03-23. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.